Literature DB >> 25956835

Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance.

Erik Mooiweer1, Andrea E van der Meulen-de Jong2, Cyriel Y Ponsioen3, C Janneke van der Woude4, Ad A van Bodegraven5, Jeroen M Jansen6, Nofel Mahmmod7, Willemijn Kremer1, Peter D Siersema1, Bas Oldenburg8.   

Abstract

BACKGROUND & AIMS: Surveillance is recommended for patients with long-term inflammatory bowel disease because they have an increased risk of colorectal cancer (CRC). To study the effectiveness of surveillance, we determined the incidence of CRC after negative findings from surveillance colonoscopies (interval CRC).
METHODS: We collected data from 1273 patients with ulcerative colitis or Crohn's disease, enrolled in a surveillance program at 7 hospitals in The Netherlands, who underwent 4327 surveillance colonoscopies from January 1, 2000, through January 1, 2014. Patients were followed up from their first surveillance colonoscopy until the last surveillance colonoscopy, colectomy, or CRC. Factors that might have contributed to the occurrence of CRC were categorized as inadequate procedures (ie, inadequate bowel preparation), inadequate surveillance (CRC occurring outside the appropriate surveillance interval), or inadequate management of dysplasia (CRC diagnosed in the same colonic segment as a previous diagnosis of dysplasia). The remaining CRC cases were classified as true interval CRCs.
RESULTS: CRC was diagnosed in 17 patients (1.3%), with an incidence of 2.5 per 1000 years of follow-up evaluation. Factors that might account for the occurrence of CRC were identified in 12 patients (70%). These were inadequate colonoscopies in 4 patients (24%), inadequate surveillance intervals in 9 patients (53%), and inadequate management of dysplasia in 2 patients (12%). The remaining 5 cases of CRC (30%) were classified as true interval CRCs.
CONCLUSIONS: In a retrospective analysis of patients with inflammatory bowel disease participating in a surveillance program, the incidence of CRC was only 1%, which supports the implementation of longer surveillance intervals. However, the fact that 30% of CRC cases were interval cancers indicates the need for variable surveillance intervals based on risk factors for CRC.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammatory Bowel Disease; Interval Colorectal Cancer; Surveillance

Mesh:

Year:  2015        PMID: 25956835     DOI: 10.1016/j.cgh.2015.04.183

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  29 in total

1.  Endoscopic Management of Complex Lesions in Patients With Inflammatory Bowel Disease.

Authors:  Anna M Buchner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-03

2.  Circulating lncRNAs associated with occurrence of colorectal cancer progression.

Authors:  Jian Shi; Xiaohua Li; Fan Zhang; Changxi Zhang; Qinghai Guan; Xuefeng Cao; Wentao Zhu; Xingyuan Zhang; Yu Cheng; Kun Ou; Qiangpu Chen; Sanyuan Hu
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

Review 3.  Precancer in ulcerative colitis: the role of the field effect and its clinical implications.

Authors:  Kathryn T Baker; Jesse J Salk; Teresa A Brentnall; Rosa Ana Risques
Journal:  Carcinogenesis       Date:  2018-01-12       Impact factor: 4.944

4.  Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence.

Authors:  Kristin E Burke; Jennifer Nayor; Emily J Campbell; Ashwin N Ananthakrishnan; Hamed Khalili; James M Richter
Journal:  Dig Dis Sci       Date:  2019-08-01       Impact factor: 3.199

5.  DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn's Colitis: Implications for Surveillance.

Authors:  David H Johnson; William R Taylor; Mohammed M Aboelsoud; Patrick H Foote; Tracy C Yab; Xiaoming Cao; Thomas C Smyrk; Edward V Loftus; Douglas W Mahoney; David A Ahlquist; John B Kisiel
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

6.  Putting Evidence into Practice: IBD Surveillance, Chromoendoscopy and Future Directions.

Authors:  J R Ten Hove; C N Bernstein; B Oldenburg
Journal:  Am J Gastroenterol       Date:  2018-03       Impact factor: 10.864

Review 7.  Clonal evolution of colorectal cancer in IBD.

Authors:  Chang-Ho R Choi; Ibrahim Al Bakir; Ailsa L Hart; Trevor A Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-08       Impact factor: 46.802

Review 8.  Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis.

Authors:  Mathurin Fumery; Parambir S Dulai; Samir Gupta; Larry J Prokop; Sonia Ramamoorthy; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-01       Impact factor: 11.382

9.  Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease.

Authors:  John B Kisiel; Pasquale Klepp; Hatim T Allawi; William R Taylor; Maria Giakoumopoulos; Tamara Sander; Tracy C Yab; Bjorn A Moum; Graham P Lidgard; Stephan Brackmann; Douglas W Mahoney; Arne Roseth; David A Ahlquist
Journal:  Clin Gastroenterol Hepatol       Date:  2018-05-15       Impact factor: 11.382

10.  Relationship between Metalloprotease-7 and -14 and Tissue Inhibitor of Metalloprotease 1 Expression by Mucosal Stromal Cells and Colorectal Cancer Development in Inflammatory Bowel Disease.

Authors:  Antonio Altadill; Noemi Eiro; Luis O González; Alejandro Andicoechea; Silvia Fernández-Francos; Luis Rodrigo; José Luis García-Muñiz; Francisco J Vizoso
Journal:  Biomedicines       Date:  2021-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.